Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.

EP: 1.Overview of Relapsed/Refractory Multiple Myeloma: Diagnosis, Treatment Options, Unmeet Needs

EP: 2.MonumenTAL-1: Long Term Follow up Efficacy

EP: 3.MonumenTAL-1: Safety and AEs

EP: 4.Managing GPRC5D Therapy: Unique AE Challenges and Patient Preparation

Now Viewing

EP: 5.Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS

EP: 6.Managing toxicities of BCMA_targeting Bispecfics

Video content above is prompted by the following:

How are the step-up and treatment doses for GPRC5D administered at your institution? Are they administered in your clinic or in the community?

• How are patients monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during step-up dosing?

Recent Videos